O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. (2nd July 2019) - Tempero, M; Oh, D; Macarulla, T; Reni, M; Cutsem, E Van; Hendifar, A; Waldschmidt, D; Starling, N; Bachet, J; Chang, H; Maurel, J; Lonardi, S; et al.